Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Jan-Feb;7(1):61-7.
doi: 10.1155/2000/587957.

A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation

J M FitzGerald  1 , D Shragge, J Haddon, B Jennings, J Lee, T Bai, P Pare, D Kassen, A Grunfeld
Affiliations
Free article
Clinical Trial

A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation

J M FitzGerald et al. Can Respir J. 2000 Jan-Feb.
Free article

Abstract

Objective: Prednisone (PRED) is recommended at discharge to reduce the relapse rate following emergency treatment for an asthmatic attack. However, PRED has systemic side effects. Inhaled anti-inflammatory medications, such as budesonide (BUD), are well tolerated. This study was designed to compare the effectiveness of PRED and BUD on relapse rate.

Design: A prospective, randomized, double-blind, double dummy, parallel group design.

Setting: Tertiary referral emergency departments.

Population studied: One hundred and eighty-five patients with acute asthma who received standard treatment with bronchodilators and systemic glucocorticosteroids in the emergency department, had a forced expiration volume in 1 s (FEV1) greater than 50% predicted and who were deemed well enough to be discharged from the emergency department.

Intervention: Patients were randomized to receive either BUD Turbuhaler 600 microg qid or PRED 40 mg in the morning for seven to 10 days. At discharge and final visit, symptoms, medication use, FEV1, peak expiratory flow (PEF) and quality of life (QoL) were assessed. Relapse rate to the emergency department during the follow-up was determined by a yes and/or no questionnaire.

Main results: The PRED (n=85) and BUD (n=90) treatment groups were comparable at baseline (emergency department discharge) for age (mean +/- SD; 27.6+/-8.5 years and 29. 2+/-8.7 years) and prebronchodilator FEV1 (1.77+/-0.79 L and 1. 75+/-0.78 L), respectively. BUD was at least as effective as PRED in preventing a relapse to the hospital; relapse rate was 10 (11.8%) during PRED treatment and nine (10.0%) for BUD treatment (95% CI PRED-BUD, -7.5% to 11.0%). Improvements in FEV1, asthma symptoms, PEF and QoL were not significantly different between treatments.

Conclusions: In patients whose acute asthma has been stabilized in the emergency department, high dose BUD may be an alternate to PRED as a follow-up treatment.

PubMed Disclaimer

Comment in

  • ACP J Club. 2000 Sep-Oct;133(2):51

Similar articles

See all similar articles

Cited by

  • An evidence-based, point-of-care tool to guide completion of asthma action plans in practice.
    Kouri A, Boulet LP, Kaplan A, Gupta S. Kouri A, et al. Eur Respir J. 2017 May 1;49(5):1602238. doi: 10.1183/13993003.02238-2016. Print 2017 May. Eur Respir J. 2017. PMID: 28461295 Free PMC article. Review.
  • Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations.
    FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J; Canadian Asthma Exacerbation Study Group. FitzGerald JM, et al. Thorax. 2004 Jul;59(7):550-6. doi: 10.1136/thx.2003.014936. Thorax. 2004. PMID: 15223858 Free PMC article. Clinical Trial.
  • International consensus on (ICON) pediatric asthma.
    Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Mäkelä M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Aït-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lødrup-Carlsen K, Lötvall J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS. Papadopoulos NG, et al. Allergy. 2012 Aug;67(8):976-97. doi: 10.1111/j.1398-9995.2012.02865.x. Epub 2012 Jun 15. Allergy. 2012. PMID: 22702533 Free PMC article.
  • Inhaled vs oral steroids for adults with chronic asthma.
    Mash B, Bheekie A, Jones PW. Mash B, et al. Cochrane Database Syst Rev. 2000;2001(2):CD002160. doi: 10.1002/14651858.CD002160. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2001;(1):CD002160. doi: 10.1002/14651858.CD002160. PMID: 10796683 Free PMC article. Updated.
  • The dose-response relationship of inhaled corticosteroids in asthma.
    Masoli M, Holt S, Weatherall M, Beasley R. Masoli M, et al. Curr Allergy Asthma Rep. 2004 Mar;4(2):144-8. doi: 10.1007/s11882-004-0060-y. Curr Allergy Asthma Rep. 2004. PMID: 14769264 Review.
See all "Cited by" articles

Publication types

MeSH terms